Literature DB >> 25658785

Aneurysm diameter as a risk factor for pretreatment rebleeding: a meta-analysis.

Hieronymus D Boogaarts1, Jasper H van Lieshout, Martinus J van Amerongen, Joost de Vries, André L M Verbeek, J André Grotenhuis, Gert P Westert, Ronald H M A Bartels.   

Abstract

OBJECT: Aneurysmal rerupture prior to treatment is a major cause of death and morbidity in aneurysmal subarachnoid hemorrhage. Recognizing risk factors for aneurysmal rebleeding is particularly relevant and might help to identify the aneurysms that benefit from acute treatment. It is uncertain if the size of the aneurysm is related to rebleeding. This meta-analysis was performed to evaluate whether an association could be determined between aneurysm diameter and the rebleeding rate before treatment. Potentially confounding factors such age, aneurysm location, and the presence of hypertension were also evaluated.
METHODS: The authors systematically searched the PubMed, Embase, and Cochrane databases up to April 3, 2013, for studies of patients with aneurysmal subarachnoid hemorrhage that reported the association between aneurysm diameter and pretreatment aneurysmal rebleeding. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria were used to evaluate study quality.
RESULTS: Seven studies, representing 2121 patients, were included in the quantitative analysis. The quality of the studies was low in 2 and very low in 5. Almost all of the studies used 10 mm as the cutoff point for size among other classes, and only one used 7 mm. An analysis was performed with this best unifiable cutoff point. Overall rebleeding occurred in 360 (17.0%) of 2121 patients (incidence range, from study to study, 8.7%-28.4%). The rate of rebleeding in small and large aneurysms was 14.0% and 23.6%, respectively. The meta-analysis of the 7 studies revealed that larger size aneurysms were at a higher risk for rebleeding (OR 2.56 [95% CI 1.62-4.06]; p = 0.00; I (2) = 60%). The sensitivity analysis did not alter the results. Five of the 7 studies reported data regarding age; 4 studies provided age-adjusted results and identified a persistent relationship between lesion size and the risk of rebleeding. The presence of hypertension was reported in two studies and was more prevalent in patients with rebleeding in one of these. Location (anterior vs posterior circulation) was reported in 5 studies, while in 4 there was no difference in the rebleeding rate. One study identified a lower risk of rebleeding associated with posterior location aneurysms.
CONCLUSIONS: This meta-analysis showed that aneurysm size is an important risk factor for aneurysmal rebleeding and should be used in the clinical risk assessment of individual patients. The authors' results confirmed the current guidelines and underscored the importance of acute treatment for large ruptured aneurysms.

Entities:  

Keywords:  GRADE = Grading of Recommendations Assessment, Development and Evaluation; SAH = subarachnoid hemorrhage; intracranial aneurysm; meta-analysis; recurrence; risk; subarachnoid hemorrhage; vascular disorders

Mesh:

Year:  2015        PMID: 25658785     DOI: 10.3171/2014.12.JNS14931

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

Review 1.  Acute rerupture after coil embolization of ruptured intracranial saccular aneurysms: A literature review.

Authors:  Kailing Li; Yunbao Guo; Ying Zhao; Baofeng Xu; Kan Xu; Jinlu Yu
Journal:  Interv Neuroradiol       Date:  2017-12-12       Impact factor: 1.610

2.  Different Hemodynamic Characteristics and Resulting in Different Risks of Rupture Between Wide-Neck and Narrow-Neck Aneurysms.

Authors:  Heng Wei; Qi Tian; Kun Yao; Jianfeng Wang; Peibang He; Yujia Guo; Wenrui Han; Wenhong Gao; Mingchang Li
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

3.  Systolic Blood Pressure Variability is a Novel Risk Factor for Rebleeding in Acute Subarachnoid Hemorrhage: A Case-Control Study.

Authors:  Qing-Song Lin; Yuan-Xiang Lin; Zhang-Ya Lin; Liang-Hong Yu; Lin-Sun Dai; De-Zhi Kang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

4.  Aneurysm characteristics and risk of rebleeding after subarachnoid haemorrhage.

Authors:  Inez Koopman; Jacoba P Greving; Irene C van der Schaaf; Albert van der Zwan; Gabriel Je Rinkel; Mervyn DI Vergouwen
Journal:  Eur Stroke J       Date:  2018-10-08

5.  Should Cerebral Angiography Be Avoided within Three Hours after Subarachnoid Hemorrhage?

Authors:  Hong An; Jaechan Park; Dong-Hun Kang; Wonsoo Son; Young-Sup Lee; Youngseok Kwak; Boram Ohk
Journal:  J Korean Neurosurg Soc       Date:  2019-08-30

6.  Risk Factors for Higher Volume of Hemorrhage in Ruptured Anterior Circulation Intracranial Aneurysms.

Authors:  Xiaolong Ya; Chaoqi Zhang; Jichao Liu; Shuo Zhang; Qian Zhang; Shuo Wang; Yong Cao; Jizong Zhao
Journal:  Front Surg       Date:  2020-11-12

7.  Elevated Glucose-Potassium Ratio Predicts Preoperative Rebleeding in Patients With Aneurysmal Subarachnoid Hemorrhage.

Authors:  Jiayin Wang; Qiangqiang Feng; Yinbin Zhang; Weizhi Qiu; Hongzhi Gao
Journal:  Front Neurol       Date:  2022-01-13       Impact factor: 4.003

8.  Rebleeding of Ruptured Intracranial Aneurysm After Admission: A Multidimensional Nomogram Model to Risk Assessment.

Authors:  Qingyuan Liu; Yi Yang; Junhua Yang; Maogui Li; Shuzhe Yang; Nuochuan Wang; Jun Wu; Pengjun Jiang; Shuo Wang
Journal:  Front Aging Neurosci       Date:  2021-09-01       Impact factor: 5.750

9.  Rs12976445 polymorphism is associated with the risk of post-SAH re-bleeding by modulating the expression of microRNA-125 and ET-1.

Authors:  Wenping Xiong; Weiqi Yao; Zeyuan Gao; Kui Liu
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.996

10.  Thromboelastography with Platelet Mapping Detects Platelet Dysfunction in Patients with Aneurysmal Subarachnoid Hemorrhage with Rebleeding.

Authors:  Qiuguang He; You Zhou; Chang Liu; Xiang Zhang; Ning Huang; Feng Wang; Guodong Liu; Yuan Cheng; Zongyi Xie
Journal:  Neuropsychiatr Dis Treat       Date:  2019-12-16       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.